KRAS and non-small cell lung carcinoma: Given that immunotherapy is a first-line treatment for NSCLC and KRAS ablation elicits an antitumor immune response64, our approach may not only enhance immunotherapy efficacy but also serve as a powerful tool for investigating KRAS-driven immunosuppression in NSCLC.